Fig. 3: CART84 selectively kills CD84-positive cells and targets primary AML blasts in vitro. | Leukemia

Fig. 3: CART84 selectively kills CD84-positive cells and targets primary AML blasts in vitro.

From: A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias

Fig. 3

A Cytotoxicity of CART84 cells towards CD84-negative (left) and CD84-positive (right) HEK-293 cells, at an E:T ratio of 4:1, assessed with the xCELLigence. B Cytotoxicity of CART84 cells against primary AML cells from patient sample #13 (see Suppl. Table 1). Data represent the mean of two CART84 productions derived from T cells of two healthy donors (BC#215 and BC#216), tested against AML cells from patient #13. One representative example out of three is shown. Statistical significance was determined with a two-way ANOVA test (multiple comparisons to UT). C Cytotoxicity of CART84 cells derived from AML patient #52 against autologous AML blasts. Details of AML diagnoses are provided in Supplementary Table 1. Statistical significance was determined with a two-way ANOVA test (multiple comparisons to UT). UT untransduced T cells. ***p < 0.001.

Back to article page